The trajectory of companies tied to Viagra's legacy presents a challenging investment scenario . While the initial boom generated substantial gains, generic alternatives have significantly eroded revenue. Investing in connected pharmaceutical companies now requires a careful assessment of proprietary safeguards, evolving medical shifts , and the po